A Multicenter Trial of Oral Zidovudine in Children with Advanced Human Immunodeficiency Virus Disease

Authors:
  • RMRoss E. Jr. McKinney
    Ross E. Jr. McKinney
  • MMMary A. Maha
    Mary A. Maha
  • ECEdward M. Connor
    Edward M. Connor
  • JFJudith Feinberg
    Judith Feinberg
  • GSGwendolyn B. Scott
    Gwendolyn B. Scott
  • MWMichael Wulfsohn
    Michael Wulfsohn
  • KMKenneth McIntosh
    Kenneth McIntosh
  • WBWilliam Borkowsky
    William Borkowsky
  • JMJohn F. Modlin
    John F. Modlin
  • PWPeggy Weintrub
    Peggy Weintrub
  • KOKaren O'Donnell
    Karen O'Donnell
  • RGRichard D. Gelber
    Richard D. Gelber
Open Access
Publisher website
Google Scholar
Abstract
Zidovudine has been shown to be an effective antiretroviral treatment in adults with human immunodeficiency virus (HIV) infection. We examined the safety of zidovudine and the tolerance of and therapeutic response to the drug in 88 children with advanced HIV disease. During a 24-week outpatient trial, zidovudine (180 mg per square meter of body-surface area per dose) was given by mouth every six hours and serial measurements were made of clinical, immunologic, and virologic indexes. Children who completed 24 weeks of treatment were permitted to continue receiving zidovudine.

This publication has 15 references indexed in Scilit: